Glucagon-like peptide-1 is a hormone your gut already makes. It is released within minutes of eating, it survives in the bloodstream for perhaps two minutes, and it does several things at once: it prompts the pancreas to release insulin in proportion to the glucose actually present, it suppresses glucagon, it slows the stomach, and it signals to the brain that eating can stop.
The drugs are engineered versions of that molecule, altered so that they last a week instead of two minutes.
The three effects that matter
In the pancreas
GLP-1 amplifies insulin release, but only when glucose is elevated. This glucose-dependence is why the class does not typically cause hypoglycemia on its own — it does not force insulin out at normal blood sugars. Combine it with insulin or a sulfonylurea, though, and the risk returns.
In the stomach
Gastric emptying slows. Food leaves the stomach later, which flattens the post-meal glucose curve and produces a longer sense of fullness. It also produces most of the side effect profile: nausea, reflux, early satiety, and the occasional sense that a meal is simply sitting there.
This effect attenuates over months, which is part of why nausea tends to fade even as the dose rises.
In the brain
This is where the weight loss largely comes from. GLP-1 receptors in the hypothalamus and the brainstem participate in the circuitry that decides you are finished eating. Agonists turn that signal up.
The drug does not make food unappealing. It makes the argument about food stop.
Patients describe the result as a reduction in “food noise” — the intrusive, recurring, low-level preoccupation with what and when to eat next. There is no good clinical instrument for it, which is a reasonable criticism of the literature, because it is the effect people talk about most.
Where tirzepatide differs
Tirzepatide is a dual agonist: it hits the GLP-1 receptor and the GIP receptor. GIP is another incretin hormone, and its role in weight regulation was genuinely contested — for years the expectation was that blocking it, not stimulating it, would help.
The clinical results have been consistently stronger than GLP-1 alone. The mechanistic explanation for why is still an area of live disagreement, involving effects on adipose tissue and possibly a reduction in nausea that permits higher effective dosing. Anyone who tells you the question is settled is ahead of the evidence.
What the mechanism does not explain
Several observed effects sit awkwardly outside the tidy story. Reduced alcohol consumption. Changes in reward response that seem to extend beyond food. Cardiovascular and renal benefits that appear larger than weight loss alone would predict — the SELECT cardiovascular data and the FLOW kidney result are the clearest examples.
These are areas of genuine, active research, and the honest position is that we are describing effects we cannot yet fully account for. That is not a reason for alarm. It is a reason to be suspicious of anyone offering a confident causal story.
The molecule-level detail for each drug is in semaglutide explained and tirzepatide explained, and the full class directory — including the older agents still widely prescribed — is in every GLP-1 medication.
Why the mechanism matters to you
Understanding that the drug works partly by slowing the stomach tells you why eating quickly makes you feel worse — and why reflux, constipation and the anaesthetic precautions before surgery all trace back to the same single mechanism. Understanding that it acts on satiety circuits tells you why appetite falls before weight does. Understanding that gastric effects attenuate tells you why week nine is usually easier than week five.
Mechanism is not trivia. It is the thing that lets you interpret your own experience instead of guessing at it.
Interpreting it does require having recorded it. Everything above predicts that your worst days cluster after the injection, and that they ease at a fixed dose over several weeks — but you can only hold that theory against your own body if the dates are written down somewhere. A month of logging dose, symptoms and meals is usually enough to turn this article into a pattern you recognise. Zenday is the tracker I suggest; what actually matters is that the dose and the symptom end up on one timeline.